Shaping the Future of Molecular Imaging - How Advances Today Will Improve Patient Outcomes Tomorrow

New molecular imaging technologies and approaches are being developed aiming to give clinicians even more detailed pictures of different types of cancer cells, select best patient candidates for specific therapies, monitor the progress of treatment and even attack individual cancer cells without affecting the surrounding tissue.

GE HealthCare is part of that future. Recently, we have announced collaborations with SOFIE Biosciences and Nucleus RadioPharma as we look to shape the next generation of radiopharmaceuticals.

---

“Our strategy for Molecular Imaging in Oncology is simply to enable precision care,” Casey says. “We’re going where we think there are specific targets in terms of biomarkers to support clinicians in getting a better idea of the biology of their patients, helping them make more personalized treatment decisions. There are significant opportunities to tackle unmet needs in Oncology through areas like FAP, Theranostics and immuno-oncology. We are working to help shape the future of Molecular Imaging by collaborating to deliver on their potential.” Julia Casey, General Manager, Molecular Imaging GE HealthCare,Pharmaceutical Diagnostics

---

If you are a pharmaceutical company interested in collaborating with GE HealthCare, please complete the registration form on the right and we’ll be in touch.

To get in touch with our R&D team, please complete the registration form